$BIIB News

B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244

Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The Norm

TD Cowen Maintains Buy on Biogen, Raises Price Target to $250

Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310

Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week

Biogen To Demonstrate Data, Additional Scientific Presentations From Its Nephrology Portfolio At American Society Of Nephrology Kidney Week

Biogen-backed Estuary nabs $93M for kidney disease gene therapy

Biogen’s Quarterly Earnings Preview: What You Need to Know

Biogen (BIIB) Stock Is Up, What You Need To Know

Biogen (BIIB) Stock May Be 49% Below Fair Value As Lupus Data Loom

What Biogen (BIIB)'s 52-Week Litifilimab CLE Data Means For Shareholders

Biogen (BIIB) Could Be 5% Undervalued After 52 Week Lupus Data

JP Morgan Upgrades Biogen to Overweight, Raises Price Target to $300

UBS Maintains Buy on Biogen, Raises Price Target to $270

RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $256

Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

Biogen Announces Data From Phase 2 Part Of Its Current AMETHYST Phase 2/3 Trial Of Litifilimab In Participants With Cutaneous Lupus Erythematosus Demonstrates 27.2% Of Patients At Week 52 Achieve Clinical Endpoint Of Clear Or Utmost Clear Skin; Litifilimab Seen To Be Generally Well Tolerated

Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?